OA10133A - Inhibition of retrovirus infection - Google Patents

Inhibition of retrovirus infection Download PDF

Info

Publication number
OA10133A
OA10133A OA60622A OA60622A OA10133A OA 10133 A OA10133 A OA 10133A OA 60622 A OA60622 A OA 60622A OA 60622 A OA60622 A OA 60622A OA 10133 A OA10133 A OA 10133A
Authority
OA
OAPI
Prior art keywords
cys
pro
lys
gly
slpi
Prior art date
Application number
OA60622A
Other languages
English (en)
Inventor
Stephen Eisenberg
Sharon M Wahl
Robert C Thompson
Original Assignee
Amgen Boulder Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc, Us Health filed Critical Amgen Boulder Inc
Publication of OA10133A publication Critical patent/OA10133A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
OA60622A 1992-09-09 1995-03-09 Inhibition of retrovirus infection OA10133A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94336992A 1992-09-09 1992-09-09

Publications (1)

Publication Number Publication Date
OA10133A true OA10133A (en) 1996-12-18

Family

ID=25479533

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60622A OA10133A (en) 1992-09-09 1995-03-09 Inhibition of retrovirus infection

Country Status (23)

Country Link
EP (1) EP0666755B1 (uk)
JP (2) JP3517238B2 (uk)
KR (1) KR100273620B1 (uk)
AT (1) ATE238062T1 (uk)
AU (1) AU681350B2 (uk)
CA (1) CA2141951C (uk)
CZ (1) CZ286953B6 (uk)
DE (1) DE69332904T2 (uk)
DK (1) DK0666755T3 (uk)
ES (1) ES2197153T3 (uk)
FI (1) FI951078L (uk)
HU (1) HU218892B (uk)
NO (1) NO315546B1 (uk)
NZ (1) NZ256246A (uk)
OA (1) OA10133A (uk)
PL (1) PL307864A1 (uk)
PT (1) PT666755E (uk)
RO (1) RO116164B1 (uk)
RU (1) RU2126266C1 (uk)
SG (1) SG48115A1 (uk)
SK (1) SK281127B6 (uk)
UA (1) UA41338C2 (uk)
WO (1) WO1994006454A2 (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT75660A (en) * 1994-03-23 1997-05-28 Tokyo Tanabe Co Novel remedy for respiratory-tract viral disease
WO1997003694A1 (en) * 1995-07-24 1997-02-06 Tokyo Tanabe Company Limited Remedy for viral diseases
DK0861085T3 (da) 1995-11-13 2005-11-21 Vitaleech Bioscience N V Antivirale isolater opnået fra igler
US7276333B1 (en) 1999-05-13 2007-10-02 Japan Science And Technology Agency Viral infection inhibitor targeting integrase N-terminal domain
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760130A (en) * 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
CA1340877C (en) * 1987-12-28 2000-01-18 Takashi Sugiyama Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
JP2804979B2 (ja) * 1988-11-28 1998-09-30 日本ケミカルリサーチ株式会社 エイズ治療および阻害剤
CA2007083A1 (en) * 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
ATE148992T1 (de) * 1989-08-16 1997-03-15 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
CA2071972A1 (fr) * 1989-12-18 1991-06-19 Bruno Guy Composition pharmaceutique destinee au traitement ou a la prevention des infections retrovirales
GR1001044B (el) * 1991-06-03 1993-04-28 Logothetou Rella Eleni Μηχανισμός διή?ησης νεοπλασματικών κυττάρων και η χρήση του αναστολέα της Ca2+ -εξαρτώμενης ουδέτερης πρωτεάσης για την παρασκευή φαρμακευτικών αντικαρκινικών συν?έσεων.

Also Published As

Publication number Publication date
CA2141951C (en) 2007-04-24
DK0666755T3 (da) 2003-08-04
SG48115A1 (en) 1998-04-17
RO116164B1 (ro) 2000-11-30
SK281127B6 (sk) 2000-12-11
ATE238062T1 (de) 2003-05-15
NO315546B1 (no) 2003-09-22
HUT75126A (en) 1997-04-28
AU4853093A (en) 1994-04-12
ES2197153T3 (es) 2004-01-01
RU95109909A (ru) 1997-03-27
CA2141951A1 (en) 1994-03-31
HU9500682D0 (en) 1995-04-28
NZ256246A (en) 1997-08-22
FI951078A0 (fi) 1995-03-08
DE69332904T2 (de) 2003-11-06
EP0666755A1 (en) 1995-08-16
NO950897D0 (no) 1995-03-08
HU218892B (hu) 2000-12-28
SK29795A3 (en) 1997-02-05
JPH08505042A (ja) 1996-06-04
CZ55995A3 (en) 1996-01-17
CZ286953B6 (en) 2000-08-16
DE69332904D1 (de) 2003-05-28
WO1994006454A3 (en) 1994-08-18
NO950897L (no) 1995-03-08
PL307864A1 (en) 1995-06-26
PT666755E (pt) 2003-09-30
FI951078A7 (fi) 1995-03-08
AU681350B2 (en) 1997-08-28
WO1994006454A2 (en) 1994-03-31
EP0666755B1 (en) 2003-04-23
JP2004002455A (ja) 2004-01-08
UA41338C2 (uk) 2001-09-17
KR100273620B1 (ko) 2000-12-15
FI951078L (fi) 1995-03-08
RU2126266C1 (ru) 1999-02-20
JP3517238B2 (ja) 2004-04-12
KR950703357A (ko) 1995-09-20

Similar Documents

Publication Publication Date Title
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
JP2656938B2 (ja) dsRNAと逆転写酵素インヒビターを含んで成るHIV感染治療のための医薬組成物
JPH11507632A (ja) 併用療法を用いたhivおよび他のウイルス感染の治療
KR19990082084A (ko) 인터페론으로 선행치료한 hcv 환자를 재치료하기 위한 제약학적 조성물
WO1995017899A2 (en) Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US6017880A (en) Inhibition of retrovirus infection
CA2141951C (en) Inhibition of retrovirus infection
EP0211835A1 (en) PHARMACEUTICAL COMPOSITIONS OF INTERLEUCIN-2 PRODUCED BY MICROBIAL ROUTE.
JPH07267874A (ja) Hiv感染に対する組合せ化学療法
US6869925B1 (en) Inhibition of retrovirus infection
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
US6011014A (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
WO1998014587A1 (en) Inhibition of hiv replication using soluble tat peptide analogs
EP0960886A1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
EP1497323B1 (en) Multiple branch peptide constructions comprising from 2 to 16 branches of the peptide rqgys or from 8 to 16 branches of the peptide rqgy providing from the hiv gp41 glycoprotein
JPWO2008050830A1 (ja) 抗hiv剤
AU763289B2 (en) Use of GM-CSF to inhibit development of drug resistance in HIV+ patients
Pomerantz et al. Therapy of human immunodeficiency virus infections
Sarin et al. Lymphadenopathy-Associated Virus) by
WO1995023610A1 (en) Pharmaceutical composition containing thymoctonan and azt
HU203971B (en) Process for producing synergetic combination pharmaceutical compositions comprising 3'-azido-3'-deoxythymidine and one more active ingredient
JPWO1998051295A1 (ja) Hiv−1プロテアーゼ阻害剤、その製造方法及び医薬組成物